U.S. Entertainment Stock News

Alto Neuroscience just received Fast Track designation from the FDA for ALTO-101, a new drug candidate aimed at treating cognitive impairment related to schizophrenia. This move could accelerate ALTO-101’s development and review process. See our latest analysis for Alto Neuroscience. The FDA’s support for ALTO-101 sparked fresh interest in Alto Neuroscience. However, despite the headline, its 1-year total shareholder return remains nearly flat while recent share price momentum has been...

Thinking about what to do with Informatica stock? You are not alone. Recent movement in the shares has caught a lot of attention, and there is no shortage of opinions out there. Right now, the stock is hovering near $24.92, and you might notice the numbers are a bit of a mixed bag. Over the past week and month, Informatica has inched up by 0.4% and 0.6% respectively, but if you look at the year-to-date performance, it is down 2.1%. The past year also shows a slight dip, with shares falling...

ClearPoint Neuro recently announced the appointment of Dr. Paul Larson as Chief Medical Officer, the unveiling of its proprietary Robotic Neuro-Navigation System for minimally invasive cranial procedures, and new insider buying from directors. The Robotic Neuro-Navigation System aims to provide greater consistency for cell and gene therapy delivery, and ClearPoint's drug delivery technology was spotlighted in strong Huntington's disease trial results from a biopharma collaborator. Let's...

Reitar Logtech Holdings recently announced the formal signing of a Strategic Cooperation Memorandum of Understanding with AI logistics company NEXX to jointly invest in a Smart Fulfillment Center project in Doha, Qatar, as part of broad plans for logistics automation in the region. This initiative not only launches a large-scale, AI-driven logistics facility but also aligns with Qatar's 2030 National Vision and the digital corridor ambitions of China's Belt and Road Initiative. We'll explore...

With a price-to-earnings (or "P/E") ratio of 9.7x Green Brick Partners, Inc. ( NYSE:GRBK ) may be sending bullish...

With a median price-to-sales (or "P/S") ratio of close to 2.8x in the Medical Equipment industry in the United States...

The Glimpse Group, Inc. ( NASDAQ:VRAR ) shareholders would be excited to see that the share price has had a great...

Anyone interested in Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) should probably be aware that the Co-Founder, Justin...

We wouldn't blame Snowflake Inc. ( NYSE:SNOW ) shareholders if they were a little worried about the fact that Vivek...

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Over the last year, a good number of insiders have significantly increased their holdings in Neurogene Inc...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Blue Bird fair value estimate is US$94.98 Blue Bird is...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Key Insights Institutions' substantial holdings in Rayonier Advanced Materials implies that they have significant...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Stitch Fix fair value estimate is US$6.57 Stitch Fix is...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...

With a price-to-earnings (or "P/E") ratio of 27x Element Solutions Inc ( NYSE:ESI ) may be sending bearish signals at...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

American Financial Group, Inc.'s ( NYSE:AFG ) dividend will be increasing from last year's payment of the same period...

If you have been watching ThredUp lately, you know it is one of those rare stocks that keeps drawing your attention. Whether you are holding after that massive 1-year surge or you are still weighing your next move, there is a lot to unpack. ThredUp has soared an eye-catching 1111.0% over the last year, with a staggering 568.8% gain year-to-date. Even after a recent 30-day dip of -10.7%, it has still notched a respectable 2.4% gain in the past week. This reminds investors that volatility can...

Ovid Therapeutics recently announced positive topline results from its Phase 1 study of OV329, a next-generation GABA-aminotransferase inhibitor targeting drug-resistant epilepsies, demonstrating significant GABAergic inhibition and strong safety outcomes in 68 healthy volunteers. This clinical milestone signals potential advancement in the treatment of drug-resistant epilepsies and attracted new institutional investors through a substantial private placement. We'll explore how OV329’s early...

On September 24, 2025, Zura Bio Limited adopted an Executive Severance Benefit Plan, outlining compensation for executives if terminated without cause or upon resignation for good reason, especially in the context of a change in control. This move comes as the company, which reported having US$154 million in cash with a reported runway of 3.5 years as of June 2025, faces scrutiny over its increasing cash burn and potential funding needs. We'll examine how concerns around Zura Bio's executive...

If you’ve been scanning the markets wondering whether now is the right time to buy, hold, or move on from Alexander & Baldwin, you’re not alone. This stock can puzzle even seasoned investors, especially after a rollercoaster of performance. Over the past five years, Alexander & Baldwin’s price has soared nearly 80%, which is impressive for a real estate-focused name. Those who’ve sat tight since 2021 are still up over 22% despite the flat year-over-year returns, and a slight dip of -0.4% in...